Blue Health Intelligence, an Amsterdam-based preventive health company, has raised €3.4 million to expand its network of clinics offering in-depth health assessments for people who do not yet feel ill. The round, announced on 30 September 2026, was led by Knop Investments, with participation from former Philips executive Jeroen Tas and entrepreneur Anna Nooshin, among others.
An earlier funding round raised more than €1.1 million, bringing the company's total disclosed funding to more than €4.5 million.
A one-hour health check for €299
Blue Health Intelligence offers a preventive health assessment that takes about an hour and costs €299. During the visit, clinicians collect hundreds of data points covering areas such as cardiovascular health, metabolism and liver and kidney function. Medical staff interpret the results, and clients can access their data through an app, allowing them to track changes over time.
The idea is to identify risk factors for chronic diseases, such as heart disease and type 2 diabetes, early enough for clients to make changes to their lifestyle or seek medical advice before serious problems develop.
Demand has been strong. More than 2,000 people have booked assessments at the company's Amsterdam location, which is fully booked through November, according to Knop Investments. That level of demand for a service that is paid for directly by consumers suggests a willingness to spend on prevention that health systems have struggled to tap.
Expansion beyond the Netherlands
The new funding will support international expansion and the development of new clinics. The company is considering Paris and Milan for its first locations outside the Netherlands, potentially opening during the first half of 2027.
Both cities have large, affluent urban populations and a strong interest in health and wellbeing. Expanding into France and Italy will, however, require the company to navigate different healthcare regulations, professional licensing rules and consumer expectations, which can make cross-border expansion of clinical services in Europe complex.
Experienced backers
The investors bring relevant expertise. Jeroen Tas held senior roles at Philips, the Dutch health technology group, including leading its innovation and strategy work in connected care and informatics. His experience in digital health and data-driven care is directly relevant to a business built on collecting and interpreting health data.
Anna Nooshin is a Dutch entrepreneur and media personality who built a large online following and consumer business. Her involvement could help Blue Health Intelligence reach younger, health-conscious consumers through channels that traditional healthcare providers rarely use.
Knop Investments' decision to lead the round reflects growing investor interest in consumer-paid preventive health models in Europe.
Why prevention is attracting investment
Europe's health systems face rising costs as populations age and chronic diseases become more common. Conditions such as cardiovascular disease, diabetes and liver disease account for a large share of healthcare spending, and many of them develop silently for years before symptoms appear.
Public health systems in most European countries are designed primarily to treat illness rather than to proactively screen healthy people in depth. Routine check-ups are typically limited, and waiting times for non-urgent appointments can be long. That creates an opening for private providers that offer fast, comprehensive assessments for consumers willing to pay.
At the same time, interest in longevity, the idea of extending the number of years lived in good health, has grown rapidly. Wearable devices, continuous glucose monitors and at-home testing have made many people more aware of their health data and more interested in acting on it.
A global trend, including India
Blue Health Intelligence's round is part of a broader global movement. On the same day, Mumbai-based Vytalyou, founded by a molecular oncologist and a radiologist, raised ₹9 crore to expand its doctor-led longevity clinics in India. The parallel shows how preventive health is attracting investment in very different markets, from Western Europe to South Asia, with business models adapted to local price points and healthcare systems.
The evidence question
Preventive health assessments also attract scrutiny. Medical experts note that screening healthy people for a wide range of markers can lead to false positives, unnecessary anxiety and additional tests or treatment. Not all measurements have strong evidence that acting on them improves long-term health outcomes.
Providers in the sector therefore face the challenge of balancing comprehensive testing with evidence-based interpretation. Blue Health Intelligence's model, in which medical staff interpret results rather than leaving clients to read raw data on their own, is intended to make the information more useful and reduce the risk of misinterpretation.
Pricing as a strategy
At €299, the assessment is priced well below many premium longevity services in the United States and the Middle East, where comprehensive scans and testing packages can cost several thousand dollars. That price point is designed to make preventive health accessible to a broader middle-class market rather than only to the very wealthy. It also positions the company to work with employers and insurers in the future, both of which have an interest in preventing costly chronic disease among their employees and policyholders. If corporate or insurance channels open up, the business could scale far faster than through individual bookings alone.
Data and digital continuity
The app-based approach could become an important part of the company's value. By allowing clients to store and track their results over time, Blue Health Intelligence can encourage repeat assessments and build a long-term relationship with its customers. Longitudinal health data, collected consistently over years, is also far more valuable for identifying meaningful changes than a single snapshot.
Handling sensitive health data comes with strict obligations under the European Union's General Data Protection Regulation, which treats health information as a special category requiring extra protection. Strong data governance will be essential as the company grows.
What comes next
With fresh capital, strong demand in Amsterdam and plans for Paris and Milan, Blue Health Intelligence is moving from a single successful clinic to a multi-country network. Its challenge will be to replicate the quality and experience of its first location in new markets while keeping its price accessible to a broad group of health-conscious consumers.
If it succeeds, it could help shift preventive health in Europe from an occasional luxury to a routine part of how people manage their wellbeing, and demonstrate that consumers are ready to invest in their future health before illness strikes.
